HUTCHMED Financial Statements From 2010 to 2025
| HMDCF Stock | USD 3.66 0.00 0.00% |
Check HUTCHMED (China) financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among HUTCHMED (China)'s main balance sheet or income statement drivers, such as , as well as many indicators such as . HUTCHMED financial statements analysis is a perfect complement when working with HUTCHMED (China) Valuation or Volatility modules.
HUTCHMED |
HUTCHMED Limited Company Profit Margin Analysis
HUTCHMED (China)'s Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current HUTCHMED (China) Profit Margin | (0.64) % |
Most of HUTCHMED (China)'s fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, HUTCHMED Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, HUTCHMED Limited has a Profit Margin of -0.6365%. This is 94.32% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The profit margin for all United States stocks is 49.88% lower than that of the firm.
HUTCHMED Limited Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining HUTCHMED (China)'s current stock value. Our valuation model uses many indicators to compare HUTCHMED (China) value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across HUTCHMED (China) competition to find correlations between indicators driving HUTCHMED (China)'s intrinsic value. More Info.HUTCHMED Limited is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the HUTCHMED (China)'s earnings, one of the primary drivers of an investment's value.About HUTCHMED (China) Financial Statements
HUTCHMED (China) stakeholders use historical fundamental indicators, such as HUTCHMED (China)'s revenue or net income, to determine how well the company is positioned to perform in the future. Although HUTCHMED (China) investors may analyze each financial statement separately, they are all interrelated. For example, changes in HUTCHMED (China)'s assets and liabilities are reflected in the revenues and expenses on HUTCHMED (China)'s income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in HUTCHMED Limited. Please read more on our technical analysis and fundamental analysis pages.
HUTCHMED Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. The company was incorporated in 2000 and is headquartered in Central, Hong Kong. Hutchison China operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 2110 people.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in HUTCHMED Pink Sheet
HUTCHMED (China) financial ratios help investors to determine whether HUTCHMED Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HUTCHMED with respect to the benefits of owning HUTCHMED (China) security.